Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07571148
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study uses existing health records and insurance claims data to understand how adults in the United States are treated with KarXT, a medication for schizophrenia. It will describe who receives KarXT, how it is used in real-world practice, and how often healthcare services such as hospital visits are used. It will also explore information recorded by clinicians about schizophrenia symptoms

Key Dates

Start date
Jan 16, 2026
Status verified
Apr 2026
Primary completion
Mar 25, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
6,876 participants (actual)

Arms

  • Arm: Adults treated with KarXT
    Adults aged ≥18 years in the United States with at least one prescription for KarXT on or after September 24, 2024 identified in linked electronic health record and claims data.

Primary Outcome Measure

Number of all-cause and schizophrenia-related healthcare encounters per participant [ Time Frame: Baseline and up to 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
VeradigmChicagoIllinois60654-

Find similar trials in Chicago, IL

By condition
Schizophrenia
By specialty
PsychiatryMental healthBehavioral health
By research site
Veradigm· Chicago, IL

Related Studies